We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees ...
Janssen Biotech has signed a definitive agreement to buy rights to XBiotech’s investigational monoclonal antibody, bermekimab, for a cash consideration of $750m.